Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Accepted 2026-03-19 00:00:00 ET · period of report 2026-03-17 · accession 0001193125-26-115929 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-19 | 2026-03-17 | TEVA | Sabag Mark | See "Remarks" | S - Sale | $30.14 | -62.1K | 224.9K | -22% | -$1.87M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-03-17 | S | D | 62,102 | $30.14 | 224,940 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.115 to $30.215, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |